Active substanceCefoperazoneCefoperazone
Similar drugsTo uncover
  • Medoceph
    powder w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Movoperiz®
    powdersolution w / m in / in 
  • Opera
    powder w / m in / in 
  • Zeperon J
    powdersolution w / m in / in 
  • Cefobide
    powdersolution w / m in / in 
    Pfizer Inc.     USA
  • Cefoperabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    LEKKO, ZAO     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    Company DEKO, LLC     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    KRASFARMA, JSC     Russia
  • Cefoperazone-Agio
    powdersolution w / m in / in 
  • Cefoperazone-Vial
    powdersolution w / m in / in 
    VIAL, LLC     Russia
  • Cefoperus®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Cephar
    powdersolution w / m in / in 
  • Dosage form: & nbsppowder for solution for intravenous and intramuscular administration
    Composition:

    1 bottle contains the active substance:

    Cefoperazone sodium equivalent to 1 g or 2 g of cefoperazone.

    Description:
    From white to light yellow, crystalline powder is hygroscopic.
    Pharmacotherapeutic group:Antibiotic-cephalosporin
    ATX: & nbsp

    J.01.D.D.12   Cefoperazone

    Pharmacodynamics:

    Medocerus is a third generation cephalosporin with a wide spectrum of action against gram-positive and gram-negative microorganisms. The bactericidal action of cefoperazone is due to inhibition of bacterial cell wall synthesis. Resistant to the action of many beta-lactamases.

    Active in vitro for a wide range of clinically relevant microorganisms.

    Gram-positive microorganisms:

    Staphylococcus aureus (producing and not producing penicillinase), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes (beta-hemolytic group streptococcus A), Streptococcus agalactiae (beta-hemolytic streptococcus group B), Streptococcus faecalis, beta-hemolytic streptococci.

    Gram-negative microorganisms:

    Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Haemophilus influenzae, Proteus mirabilis, Proteus vulgaris, Morganella morganii (formerly Proteus morganii), Providencia rettgeri (formerly Proteus rettgeri), Providencia spp., Serratia spp. (including S. marcescens), Salmonella and Shigella spp., Pseudomonas aeruginosa and some others Pseudomonas, Acinetobacter calcoaceticus, Neisseria gonorrhoeae, Neisseria meningitidis, Bordetella pertussis, Yersinia enterocolitica.

    Anaerobic microorganisms

    Gram-positive and Gram-negative cocci (including Peptococcus spp., Peptostreptococcus spp. and Veillonella spp.)

    Gram-positive rods (including Clostridium spp., Eubacterium spp. and Lactobacillus spp.).

    Gram-negative rods (including many strains Bacteroides fragilis and others representatives Bacteroides spp., Fusobacterium spp.).

    Pharmacokinetics:The connection of cefoperazone with proteins is 82-93%. Maximum concentrations of cefoperazone after intramuscular injection of 1 g or 2 g (65 μg / ml or 97 μg / ml, respectively) are achieved within 1-2 hours.

    After 15 minutes after a single intravenous administration, the following concentrations of cefoperazone in the blood serum are achieved: 153 μg / ml - with the administration of 1 g; 252 μg / ml - with the introduction of 2 g; 340 μg / ml - with the introduction of 3 g and 506 μg / ml - with the introduction of 4 g. Cefoperazone achieves therapeutic concentrations in all the fluids and tissues of the body, including ascites and cerebrospinal fluid (meningitis), urine, bile and gall bladder wall, sputum and lungs, palatine tonsils and mucous membranes of the sinuses, atrial, kidney, ureter , prostate, testicles, uterus and fallopian tubes, bones, cord blood and amniotic fluid. Cefoperazone is excreted with bile and urine. The concentration of cefoperazone in bile varies from 66 μg / ml after 30 minutes to 6,000 μg / ml 3 h after intravenous administration of 2 g of the drug.

    12 hours after the administration of different dosages by different methods, in individuals with normal kidney function with the kidneys, an average of 20-30% of cefoperazone is excreted.After a 15-minute intravenous infusion of 2 g of cefoperazone, the maximum concentration of the drug in the urine is 2200 μg / ml. After intramuscular injection of 2 g of the drug, the maximum concentration in urine is 1000 μg / ml and is maintained at the therapeutic level for 2 hours.

    The average half-life of cefoperazone from serum is approximately 2 hours and does not depend on the mode of administration; when cholestasis - increases to 4.3-11 h; in unborn babies with a reduced body weight is 6-10 hours, and in children aged 2 months to 11 years, 2.2 hours.

    Cefoperazone is poorly excreted by dialysis. In small amounts excreted in breast milk.

    In patients with impaired liver function increases the half-life of the drug from the blood serum and its excretion in the urine. In patients with renal-hepatic insufficiency cefoperazone can accumulate in the blood serum.

    In patients with renal insufficiency there were no significant differences in the pharmacokinetics of cefoperazone.

    Indications:

    Infectious-inflammatory diseases caused by microorganisms sensitive to cefoperazone.

    - infections of the upper and lower respiratory tract;

    - urinary tract infections;

    - intra-abdominal infections (including peritonitis, cholecystitis, cholangitis);

    - sepsis;

    - meningitis;

    - infections of the skin and soft tissues;

    - infection of bones and joints;

    - Infectious-inflammatory diseases of the pelvic organs (endometritis, gonorrhea and other infections of the genital tract).

    Prevention of infectious postoperative complications in abdominal, gynecological, cardiovascular and orthopedic operations.

    Contraindications:Hypersensitivity to cefoperazone and other beta-lactam antibiotics.
    Carefully:
    Severe violations of the kidney and liver, with a history of colitis.
    Pregnancy and lactation:

    In pregnancy, the drug is used only if the expected benefit to the mother exceeds the potential risk to the fetus.

    If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.

    Dosing and Administration:

    Intravenously (intravenously) or intramuscularly (in / m).

    Adults - 2-4 g / day in equal parts every 12 hours; in case of serious infections, the dose can be increased up to 8 g / day in equal parts every 12 hours.Treatment with the drug can begin before the results of a study of the sensitivity of microorganisms.

    With uncomplicated gonococcal urethritis, a one-time intramuscular injection of 500 mg of the drug is recommended.

    In the treatment of infections caused by Streptococcus pyogenes, in adults and children, the duration of therapy should be at least 10 days.

    Prevention of postoperative complications - 1 g or 2 g of the drug intravenously for 30-90 minutes before the start of the operation, with a repeat every 12 hours (in most cases for no more than 24 hours). In case of operations with an increased risk of infection (for example, surgery in the colorectal area) or if the infection is especially dangerous (for example, in open-heart surgery or joint replacement), the drug can be prevented for 72 hours after the operation is completed.

    In case of impaired renal function - 2-4 g / day. For patients with a glomerular filtration rate below 18 ml / min or a creatinine concentration above 3.5 mg / dl, the dose should not exceed 4 g / day.

    When hemodialysis, the half-life of cefoperazone from the blood serum decreases slightly, so the drug should be administered after the end of dialysis.

    With severe violations of the liver, severe obstruction of the biliary tract The daily dose of the drug should not exceed 2 g.

    In patients with renal-hepatic insufficiency, the concentration cefoperazone in the blood and, if necessary, adjust the dose. Detyam - 50-200 mg / kg body weight / day in equal parts every 8-12 hours. The maximum daily dose is 12 g. At intravenous jet slow introduction the maximum single dose makes 50 mg / kg, duration of introduction - not less than 3-5 minutes. Newborn (<8 days) - 50-200 mg / kg body weight / day in equal parts every 12 hours. The drug is injected deep in the / m into the large gluteus muscle or to the front surface of the thigh. For IV injection, the maximum single dose is 2 g; duration of administration - at least 3-5 minutes. Duration iv in the drip introduction is 15-60 min. DThe oases and duration of treatment are determined by the nature and severity of the infection and are set individually.

    Preparation of solutions

    Intramuscular injection

    For the introduction, it is recommended to dilute the preparation in two stages: 1) first, the necessary amount of sterile water for injections is added to the contents of the vial (see table) and shaken vigorously until the powder is completely dissolved.The prepared solution is maintained until the small air bubbles formed during the dissolution process disappear; 2) the required amount of 2% lidocaine solution is added to the resulting solution and mixed.

    Contents in the vial

    1 stage Sterile water volume

    Stage 2 The volume of a 2% solution of lidocaine

    The final volume

    Concentration

    solution of cefoperazone

    1 g

    2.8 ml

    1.0 ml

    4.0 ml

    250 mg / ml

    2 grams

    5.4 ml

    1.8 ml

    8.0 ml

    250 mg / ml

    Intravenous administration

    To prepare a solution for intravenous administration, 5 ml of solvent per g of cefoperazone are used. The contents of the vial are dissolved in any of the following compatible solutions: 5% or 10% dextrose injection, 5% dextrose injection and 0.9% or 0.2% sodium chloride solution for injection, 0.9% sodium chloride solution for injections, Ringer's lactate solution, sterile water for injection. The solution is thoroughly mixed and the entire amount of the resulting solution is diluted with one of the above (except water) solvents for intravenous administration.

    The prepared solution can be used both in the form of continuous infusion, and in the form of intermittent administration.

    Continuous infusion - the stock solution is diluted to a solution with a concentration of 2-25 mg / ml cefoperazone.

    Intermittent infusion - the contents of one bottle are dissolved in 20-40 ml of a compatible sterile solution for intravenous administration and injected for 15-30 minutes. In accordance with the requirements of good clinical practice, only freshly prepared solutions are recommended, but the solution remains stable when stored for 24 hours at room temperature and for 120 hours when stored in a refrigerator (2-8 ° C).

    Side effects:

    From the digestive system: diarrhea, nausea, vomiting, pseudomembranous colitis, a slight reversible increase in the activity of "hepatic" transaminases - aspartate aminotransferase (ACT), alanine aminotransferase (ALT) and alkaline phosphatase.

    Allergic reactions: maculopapular rash, hives, itching, fever, Stevens-Johnson syndrome, anaphylactic shock. The risk of developing allergic reactions is higher in patients with a tendency to allergic reactions (especially penicillin) in the anamnesis.

    From the hematopoiesis: a slight decrease in the level of neutrophils,reversible neutropenia (with long-term treatment), false-positive direct Coombs test, decrease in hemoglobin and hematocrit, transient eosinophilia, hypoprothrombinemia, anemia, bleeding.

    Local reactions: transient painful sensations (with intramuscular injection), phlebitis at the site of infusion (with intravenous injection through the catheter).

    Overdose:

    Symptoms: neurological disorders, including convulsions.

    Treatment: sedative therapy. Effective hemodialysis, especially in patients with impaired renal function.

    Interaction:

    Ethanol. When drinking alcohol during treatment with the drug and for the next 5 days after its administration, disulfiram-like reactions characterized by "hot flashes", sweating, headache and tachycardia were recorded, so patients should be warned about the possibility of their appearance when drinking alcoholic beverages against the background of drug treatment. For patients who are on oral or parenteral artificial feeding, solutions containing ethanol.

    Aminoglycosides. Solutions of the drug and aminoglycosides should not be mixed, given the pharmaceutical incompatibility between them.If combined therapy with the drug and aminoglycoside is carried out, the two drugs are administered by successive infusions using two separate intravenous catheters. Cefoperazone should be administered before the administration of the aminoglycoside. When treating aminoglycosides, it is recommended to monitor kidney function.

    Indirect anticoagulants (coumarin and indanedione derivatives), heparin, thrombolytics can cause bleeding. In such cases, prothrombin time or an international normalized ratio should be monitored (MHO). When appointing anticoagulant therapy during or after treatment with cefoperazonom, the dose of anticoagulants should be adjusted. An effective agent for the therapy of cephalosporin mediated coagulopathy is vitamin K.

    "Loop" diuretics. Joint use of the drug with loop diuretics can lead to the development of nephrotoxic action. It is necessary to monitor the serum creatinine concentration within 48 hours from the onset of administration and periodically during co-therapy.

    Laboratory Tests: during the reception of cephalosporins can be a positive direct antiglobulin test Coombs, a false positive reaction to glucose with a solution of Benedict or Felling.

    Cefoperazone is incompatible with aminoglycosides, amifostine, filgrastin, labetalol, meperidine, nicardipine, ondansetron, perphenazine, pethidine, promethazine, agrarbin, vinorelbine.

    Special instructions:

    Hypersensitivity

    Before treatment it is necessary to collect a complete allergological anamnesis in order to identify the patient's hypersensitivity to cephalosporins, penicillins and other medicines. In case of an allergic reaction, it is necessary to cancel the drug and prescribe adequate therapy.

    Impaired liver function

    Cefoperazone is largely excreted with bile. In patients with liver disease or bile duct obstruction, the half-life of cefoperazone usually lengthens, and the excretion of the drug by the kidneys increases. But even with severe violations of liver function in bile, therapeutic concentrations of cefoperazone are achieved, and the half-life is prolonged only 2-4 times.

    Clostrifium difficile associated diarrhea is observed against the background of almost all antibacterial drugs, including cefoperazone, and is manifested from mild forms of diarrhea to severe colitis with a fatal outcome. Treatment with antibacterial drugs leads to a disruption of the normal microflora of the colon, resulting in an increased growthClostrifium difficile, producing toxins A and B, which lead to the development of Clostrifiumdifficile associated diarrhea. Hypertoxin-producing strains Clostrifium difficile lead to an increase in morbidity and mortality, since they can be resistant to antibiotic therapy. All cases of diarrhea in patients with antibiotic therapy and 2-3 weeks after cessation of treatment should be considered as suspicious for development Clostrifium difficile associated diarrhea. In mild cases, it is sufficient to discontinue treatment and apply ion-exchange resins (colestramine, colestipol), in severe cases, compensation for loss of fluid, electrolytes and protein, the appointment of vancomycin, bacitracin or metronidazole. Do not use drugs that inhibit the intestinal motility.

    General instructions

    In the treatment of cefoperazonom in rare cases, vitamin K deficiency develops. Its cause is probably suppression of normal intestinal microflora, which synthesizes this vitamin. The risk group can include patients receiving malnutrition, having a violation of food intake (for example, in cystic fibrosis) and for a long time on parenteral nutrition. In such patients, it is necessary to monitor prothrombin time and, in the presence of indications, prescribe vitamin K.

    With prolonged treatment, excessive growth of insensitive microorganisms is possible. Patients should be carefully observed during treatment. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system. This is especially important in the treatment of newborns, especially premature babies, and small children.

    Impact on laboratory test results

    When using a solution of Benedict or Feling, a false-positive reaction to glucose in the urine can be observed. Possible false positive test Coombs.

    Use in infants

    If it is necessary to prescribe the drug for premature and newborn children, both the expected positive effects and the possible risk associated with treatment should be considered. In newborns with nuclear jaundice cefoperazone Do not displace bilirubin from the connection with plasma proteins.

    Effect on the ability to drive transp. cf. and fur:The drug does not affect the ability to drive vehicles and maintain machinery.
    Form release / dosage:
    Powder for the preparation of solution for intravenous and intramuscular injection.
    Packaging:

    By 1.0 g and 2.0 g in glass colorless type I vials (EP).

    The bottles are sealed with rubber stoppers and crimped with aluminum caps.

    1 bottle with instructions for use in a cardboard box.

    For 100 bottles (for hospitals), together with an equal number of instructions for use in a cardboard pack.

    Storage conditions:Keep in dry the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N011311 / 01
    Date of registration:12.04.2010
    Expiration Date:Unlimited
    The owner of the registration certificate:Medocemi Co., Ltd.Medocemi Co., Ltd. Cyprus
    Manufacturer: & nbsp
    Representation: & nbspMEDOKEMI LTD. MEDOKEMI LTD. Cyprus
    Information update date: & nbsp26.04.2018
    Illustrated instructions
      Instructions
      Up